The Asia-Pacific sarcopenia treatment market is expected to reach USD 861,882.42 thousand by 2030 from USD 547,450.80 thousand in 2022, growing at a CAGR of 5.9% in the forecast period of 2023 to 2030 Market Segmentation Asia-Pacific Sarcopenia Treatment Market, By Treatment Type (Medications, Vitamin/Dietary Supplements, and Others), Type (Primary Sarcopenia and Secondary Sarcopenia), Stages (Pre-Sarcopenia, Sarcopenia, and Severe Sarcopenia), Route Of Administration (Oral, Injectable, and Others), Gender (Male and Female), End User (Hospitals, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others), Country (Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, New Zealand, Taiwan, And Rest Of Asia-Pacific) - Industry Trends and Forecast to 2030 Overview of Asia-Pacific Sarcopenia Treatment Market Dynamics Driver • Rising prevalence of sarcopenia Restrain • Lack of standardized diagnosis Opportunity • Strategic initiatives by key market players Market Players Some of the key market players operating in the Asia-Pacific sarcopenia treatment market are listed below: • Abbott • Nestlé Health Science (A subsidiary of Nestlé S.A.) • Novartis AG • Sanofi • Haleon Group of Companies • BASF SE • DSM • Fermenta Biotech Limited • AstaReal Co., Ltd. • Metagenics • Wellona Pharma • The Vitamin Company India • Healing Pharma India Pvt. Ltd • Others

1 INTRODUCTION 30 1.1 OBJECTIVES OF THE STUDY 30 1.2 MARKET DEFINITION 30 1.3 OVERVIEW OF THE ASIA - PACIFIC SARCOPENIA TREATMENT MARKET 30 1.4 CURRENCY AND PRICING 32 1.5 LIMITATIONS 32 1.6 MARKETS COVERED 32 2 MARKET SEGMENTATION 35 2.1 MARKETS COVERED 35 2.2 GEOGRAPHICAL SCOPE 36 2.3 YEARS CONSIDERED FOR THE STUDY 37 2.4 DBMR TRIPOD DATA VALIDATION MODEL 38 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 41 2.6 MULTIVARIATE MODELLING 42 2.7 TREATMENT TYPE SEGMENT LIFELINE CURVE 42 2.8 MARKET END USER COVERAGE GRID 43 2.9 DBMR MARKET POSITION GRID 44 2.10 VENDOR SHARE ANALYSIS 46 2.11 SECONDARY SOURCES 47 2.12 ASSUMPTIONS 47 3 EXECUTIVE SUMMARY 48 4 PREMIUM INSIGHTS 51 4.1 PESTEL ANALYSIS 52 4.2 PORTER’S FIVE FORCES MODEL 53 4.3 CURRENT STATUS OF EMERGING DRUGS FOR SARCOPENIA TREATMENT 54 5 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET: REGULATIONS 55 5.1 REGULATIONS IN U.S 55 5.2 REGULATIONS IN EUROPE 55 5.3 REGULATIONS IN AUSTRALIA 56 5.4 REGULATIONS IN SOUTH AFRICA 56 6 MARKET OVERVIEW 57 6.1 DRIVERS 59 6.1.1 RISING PREVALENCE OF SARCOPENIA 59 6.1.2 GROWING AWARENESS OF SARCOPENIA AND ITS DETRIMENTAL EFFECTS ON HEALTH 59 6.1.3 LIFESTYLE FACTORS SUCH AS POOR NUTRITION AND SEDENTARY BEHAVIOUR 60 6.2 RESTRAINTS 61 6.2.1 LACK OF STANDARDIZED DIAGNOSIS 61 6.2.2 HIGH COST OF TREATMENT AND INTERVENTIONS 61 6.3 OPPORTUNITIES 62 6.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS 62 6.3.2 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES 62 6.4 CHALLENGES 63 6.4.1 COMPLICATIONS ASSOCIATED WITH THE SARCOPENIA TREATMENT 63 6.4.2 STRINGENT GOVERNMENT RULES AND REGULATION FOR PRODUCT APPROVAL 64 7 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE 65 7.1 OVERVIEW 66 7.2 VITAMIN/DIETARY SUPPLEMENTS 69 7.2.1 VITAMIN SUPPLEMENTS 70 7.2.2 PROTEIN SUPPLEMENTS 70 7.2.3 FATTY ACID SUPPLEMENTS 70 7.2.4 CREATINE 70 7.2.5 WHEY PROTEINS 70 7.2.6 L-CARNITINE 70 7.2.7 SOY 70 7.2.8 BETA-ALANINE 70 7.2.9 OSTARINE 70 7.2.10 COLLAGEN PEPTIDES 70 7.2.11 LIGANDROL 71 7.2.12 BRANCH-CHAIN AMINO ACIDS 71 7.2.13 HYDROXYMETHYLBUTYRATE (HMB) 71 7.2.14 MEDIUM CHAIN TRIGLYCERIDES 71 7.2.15 OTHERS 71 7.3 MEDICATIONS 71 7.3.1 OFF LABEL DRUGS 72 7.3.2 EMERGING DRUGS 72 7.3.2.1 ACE INHIBITORS 72 7.3.2.2 APPETITE STIMULANTS 72 7.3.2.3 ORAL ANTIDIABETIC DRUGS 72 7.3.2.4 OTHERS 73 7.4 OTHERS 73 8 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET, BY TYPE 74 8.1 OVERVIEW 75 8.2 PRIMARY SARCOPENIA 78 8.2.1 VITAMIN/DIETARY SUPPLEMENTS 78 8.2.2 MEDICATIONS 78 8.2.3 OTHERS 78 8.3 SECONDARY SARCOPENIA 79 8.3.1 VITAMIN/DIETARY SUPPLEMENTS 79 8.3.2 MEDICATIONS 79 8.3.3 OTHERS 79 9 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET, BY STAGES 80 9.1 OVERVIEW 81 9.2 PRE-SARCOPENIA 84 9.3 SARCOPENIA 84 9.4 SEVERE SARCOPENIA 85 10 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 86 10.1 OVERVIEW 87 10.2 ORAL 90 10.3 INJECTABLES 90 10.4 OTHERS 91 11 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET, BY GENDER 92 11.1 OVERVIEW 93 11.2 MALE 96 11.3 FEMALE 96 12 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET, BY END USER 97 12.1 OVERVIEW 98 12.2 HOSPITALS 101 12.2.1 PUBLIC 101 12.2.2 PRIVATE 101 12.3 SPECIALTY CLINICS 102 12.4 HOME HEALTHCARE 102 12.5 OTHERS 103 13 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL 104 13.1 OVERVIEW 105 13.2 DIRECT TENDER 108 13.3 RETAIL SALES 108 13.3.1 HOSPITAL PHARMACIES 109 13.3.2 ONLINE PHARMACIES 109 13.3.3 OTHERS 109 13.4 OTHERS 109 14 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET, BY REGION 110 14.1 ASIA-PACIFIC 113 14.1.1 JAPAN 120 14.1.2 CHINA 127 14.1.3 SOUTH KOREA 133 14.1.4 INDIA 139 14.1.5 AUSTRALIA 145 14.1.6 SINGAPORE 151 14.1.7 THAILAND 157 14.1.8 MALAYSIA 163 14.1.9 INDONESIA 169 14.1.10 PHILIPPINES 175 14.1.11 VIETNAM 181 14.1.12 NEW ZEALAND 187 14.1.13 TAIWAN 193 14.1.14 REST OF ASIA-PACIFIC 199 15 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET, COMPANY LANDSCAPE 200 15.1 COMPANY SHARE ANALYSIS: ASIA - PACIFIC 200 16 SWOT ANALYSIS 201 17 COMPANY PROFILE 202 17.1 ABBOTT 202 17.1.1 COMPANY SNAPSHOT 202 17.1.2 REVENUE ANALYSIS 202 17.1.3 COMPANY SHARE ANALYSIS 203 17.1.4 PRODUCT PORTFOLIO 203 17.1.5 RECENT DEVELOPMENT 203 17.2 NESTLÉ HEALTH SCIENCE (A SUBSIDIARY OF NESTLÉ S.A.) 204 17.2.1 COMPANY SNAPSHOT 204 17.2.2 REVENUE ANALYSIS 204 17.2.3 COMPANY SHARE ANALYSIS 205 17.2.4 PRODUCT PORTFOLIO 205 17.2.5 RECENT DEVELOPMENT 205 17.3 NOVARTIS AG 206 17.3.1 COMPANY SNAPSHOT 206 17.3.2 REVENUE ANALYSIS 206 17.3.3 COMPANY SHARE ANALYSIS 207 17.3.4 PRODUCT PORTFOLIO 207 17.3.5 PIPELINE PORTFOLIO 207 17.3.6 RECENT DEVELOPMENT 207 17.4 SANOFI 208 17.4.1 COMPANY SNAPSHOT 208 17.4.2 REVENUE ANALYSIS 208 17.4.3 COMPANY SHARE ANALYSIS 209 17.4.4 PRODUCT PORTFOLIO 209 17.4.5 RECENT DEVELOPMENT 209 17.5 HALEON GROUP OF COMPANIES 210 17.5.1 COMPANY SNAPSHOT 210 17.5.2 REVENUE ANALYSIS 210 17.5.3 COMPANY SHARE ANALYSIS 211 17.5.4 PRODUCT PORTFOLIO 211 17.5.5 RECENT DEVELOPMENT 211 17.6 ASTAREAL CO., LTD 212 17.6.1 COMPANY SNAPSHOT 212 17.6.2 PRODUCT PORTFOLIO 212 17.6.3 RECENT DEVELOPMENT 212 17.7 BASF SE 213 17.7.1 COMPANY SNAPSHOT 213 17.7.2 REVENUE ANALYSIS 213 17.7.3 PRODUCT PORTFOLIO 214 17.7.4 RECENT DEVELOPMENT 214 17.8 BIOGEN SA 215 17.8.1 COMPANY SNAPSHOT 215 17.8.2 PRODUCT PORTFOLIO 215 17.8.3 RECENT DEVELOPMENT 215 17.9 BIOTHRIVE SCIENCES 216 17.9.1 COMPANY SNAPSHOT 216 17.9.2 PRODUCT PORTFOLIO 216 17.9.3 RECENT DEVELOPMENT 216 17.10 DSM 217 17.10.1 COMPANY SNAPSHOT 217 17.10.2 REVENUE ANALYSIS 217 17.10.3 PRODUCT PORTFOLIO 218 17.10.4 RECENT DEVELOPMENT 218 17.11 FERMENTA BIOTECH LIMITED 219 17.11.1 COMPANY SNAPSHOT 219 17.11.2 REVENUE ANALYSIS 219 17.11.3 PRODUCT PORTFOLIO 220 17.11.4 RECENT DEVELOPMENT 220 17.12 HEALING PHARMA INDIA PVT. LTD 221 17.12.1 COMPANY SNAPSHOT 221 17.12.2 PRODUCT PORTFOLIO 221 17.12.3 RECENT DEVELOPMENT 221 17.13 METAGENICS 222 17.13.1 COMPANY SNAPSHOT 222 17.13.2 PRODUCT PORTFOLIO 222 17.13.3 RECENT DEVELOPMENT 222 17.14 THE VITAMIN COMPANY INDIA 223 17.14.1 COMPANY SNAPSHOT 223 17.14.2 PRODUCT PORTFOLIO 223 17.14.3 RECENT DEVELOPMENT 223 17.15 WELLONA PHARMA 224 17.15.1 COMPANY SNAPSHOT 224 17.15.2 PRODUCT PORTFOLIO 224 17.15.3 RECENT DEVELOPMENT 224 17.16 ARMGO PHARMA, INC 225 17.16.1 COMPANY SNAPSHOT 225 17.16.2 PIPELINE PORTFOLIO 225 17.16.3 RECENT DEVELOPMENT 225 17.17 BIOPHYTIS 226 17.17.1 COMPANY SNAPSHOT 226 17.17.2 PIPELINE PORTFOLIO 226 17.17.3 RECENT DEVELOPMENT 226 17.18 DYSTROGEN THERAPEUTICS CORP 227 17.18.1 COMPANY SNAPSHOT 227 17.18.2 PIPELINE PORTFOLIO 227 17.18.3 RECENT DEVELOPMENT 227 17.19 IMMUNOFORGE INC 228 17.19.1 COMPANY SNAPSHOT 228 17.19.2 PIPELINE PORTFOLIO 228 17.19.3 RECENT DEVELOPMENT 228 17.20 MYMD PHARMACEUTICALS 229 17.20.1 COMPANY SNAPSHOT 229 17.20.2 PIPELINE PORTFOLIO 229 17.20.3 RECENT DEVELOPMENT 229 17.21 NMD PHARMA A/S 230 17.21.1 COMPANY SNAPSHOT 230 17.21.2 PIPELINE PORTFOLIO 230 17.21.3 RECENT DEVELOPMENT 230 17.22 ONCOCROSS CO., LTD 231 17.22.1 COMPANY SNAPSHOT 231 17.22.2 PIPELINE PORTFOLIO 231 17.22.3 RECENT DEVELOPMENT 231 17.23 OPKO HEALTH, INC 232 17.23.1 COMPANY SNAPSHOT 232 17.23.2 REVENUE ANALYSIS 232 17.23.3 PIPELINE PORTFOLIO 233 17.23.4 RECENT DEVELOPMENT 233 17.24 REGENERON PHARMACEUTICALS INC 234 17.24.1 COMPANY SNAPSHOT 234 17.24.2 REVENUE ANALYSIS 234 17.24.3 PIPELINE PORTFOLIO 235 17.24.4 RECENT DEVELOPMENT 235 17.25 REJUVENATE BIOMED NV 236 17.25.1 COMPANY SNAPSHOT 236 17.25.2 PIPELINE PORTFOLIO 236 17.25.3 RECENT DEVELOPMENT 236 18 QUESTIONNAIRE 237 19 RELATED REPORTS 241